Mainz Biomed (NASDAQ:MYNZ) Trading Up 5.4% – What’s Next?

Shares of Mainz Biomed (NASDAQ:MYNZ) shot up 5.4% during trading on Tuesday . The company traded as high as $2.34 and last traded at $2.33. 178,024 shares traded hands during mid-day trading, an increase of 40% from the average session volume of 127,112 shares. The stock had previously closed at $2.21.

Analysts Set New Price Targets

Separately, Maxim Group began coverage on shares of Mainz Biomed in a research note on Friday, February 14th. They issued a “buy” rating and a $14.00 target price for the company.

Mainz Biomed Stock Performance

The business’s 50 day moving average is $3.28 and its 200 day moving average is $5.23. The company has a market capitalization of $5.40 million, a price-to-earnings ratio of -0.04 and a beta of 0.50.

Institutional Trading of Mainz Biomed

An institutional investor recently bought a new position in Mainz Biomed stock. Virtu Financial LLC purchased a new position in shares of Mainz Biomed (NASDAQ:MYNZ) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 18,330 shares of the company’s stock, valued at approximately $79,000. Virtu Financial LLC owned about 0.92% of Mainz Biomed at the end of the most recent quarter.

Mainz Biomed Company Profile

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.